TrialInternational journal of clinical oncology2025

A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study.

Toru Aoyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.